Det primære sammensatte endpoint var død og reinfarkt (re- MI) senest 30 dage efter randomisering. m
The incidence of death/ re-MI at Day 30 was significantly reduced from 11.1% for the control group to 9.7% for the fondaparinux group (hazard ratio 0.86, 95% CI, 0.77, 0.96, p = 0.008).